Overview Randomized Trial for Mixed Acute Rejection Status: Completed Trial end date: 2013-03-01 Target enrollment: Participant gender: Summary This study is being conducted to determine how safe and effective using an immune cell (b cell) depleting therapy and/or Thymoglobulin is in patients with a kidney transplant who are experiencing certain types of rejection. Phase: Phase 2 Details Lead Sponsor: University of CincinnatiTreatments: AcetaminophenAntilymphocyte SerumBortezomibDiphenhydramineHistamine AntagonistsHistamine H1 AntagonistsMethylprednisoloneMethylprednisolone acetateMethylprednisolone HemisuccinatePrednisolonePrednisolone acetatePrednisolone hemisuccinatePrednisolone phosphateRituximabThymoglobulin